Docket No : 0102258 00375US2

Application No. 10/594,990 Amendment dated July 20, 2009 Reply to Office Action of April 21, 2009

AMENDMENTS TO THE CLAIMS

What is claimed is:

(Currently Amended) A method for treating sickle cell anemia or treating thalassemia in a patient in need thereof comprising administering to a patient in need thereof, a therapeutically effective amount of N-hydroxy-L-arginine, isosorbide dinitrate, isosorbide mononitrate or a mixture of two or more thereof, and at least one antioxidant-hydralazine compound or a pharmaceutically acceptable salt thereof.

2 – 4 (Cancelled)

5. (Currently amended) The method of claim [[4]] 1, wherein the hydralazine compound is hydralazine hydrochloride.

6 - 20. (Cancelled).

21. (New) The method of claim 1, wherein the hydralazine compound is selected from the group consisting of budralazine, cadralazine, dihydralazine, endralazine, hydralazine, pildralazine and todralazine.

22. (New) A method for treating thalassemia in a patient in need thereof comprising administering to a patient in need thereof, a therapeutically effective amount of N-hydroxy-Larginine, isosorbide dinitrate, isosorbide mononitrate or a mixture of two or more thereof, and at least one antioxidant.

2

Application No. 10/594,990 Docket No.: 0102258,00375US2

Amendment dated July 20, 2009 Reply to Office Action of April 21, 2009

teply to office rectain of replicati, 2005

23. (New) The method of claim 22, wherein the antioxidant is selected from the group consisting of budralazine, cadralazine, dihydralazine, endralazine, hydralazine, pildralazine and todralazine.

24. (New) The method of claim 22, wherein the antioxidant is a hydralazine compound or a pharmaceutically acceptable salt thereof.

25. (New) The method of claim 24, wherein the hydralazine compound is hydralazine hydrochloride.